Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
But the pace of biopharma asset deals dips. Are the two trends related?
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
And four other potential targets that could make sense for the beleaguered group.
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.